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1. Introduction 
Demands for allogeneic blood transfusion in cardiac surgery were still high two decades 
ago. Today there is a gradual decline in transfusion requirements owing to recent advances 
in  cardiac surgery and related specialties that have together developed  techniques for peri-
operative blood salvage and its autotransfusion; this trend continues to  progress towards 
bloodless surgery. Its milestones have included a refinement of surgical methods, a better 
understanding of bleeding pathology related to extracorporeal circulation and an 
introduction of coagulation monitoring during surgery, using point-of-care testing 
[1,2,3,4,5]. A significant advancement in extracorporeal circulation came with the 
development of less aggressive, more biocompatible and miniature-circuit systems [6, 7]. As 
a result, allogeneic blood transfusion is currently not needed in over 50% of all surgical 
procedures and in almost 100 % of coronary heart operations [8,9]. However, over 40 % of 
patients undergoing cardiac surgery still require allogeneic blood transfusion; of them, 5-7 
% show an excessive blood loss (more than a normal circulating blood volume), 10-15 % 
have a large blood loss (more than 2000 ml) and about 15-20 % have a moderate blood loss 
(1000 ml to 2000 ml) during the day of surgery up to 7 am next day. The average transfusion 
requirement ranges between 2 and 4 units of packed red blood cells (PRBC) per adult 
patient, depending on the centre. Cardiac surgery centers commonly utilize 10 to 15 % of the 
RBCs production of the regional blood bank centers [10].  
In the last two decades, the efforts to develop techniques for refinements of surgical 
methods and peri-operative blood salvage have intensified because of an increase in the 
number of reoperations and surgery on elderly, polymorbid patients with preoperative 
anemia. These are the major components of a multi-modality strategy that involves the pre-
operative preparation of a patient, surgical procedures, drug administration and 
homeostatic maintenance (Table 1).  
2. Autotransfusion 
Autotransfusion in cardiac surgery can be divided into three steps according to collection 
time and the method used, namely, pre-operative autologous blood donation, intra-
operative blood collection and post-operative  blood salvage. 
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Modality Intervetion 
Preoperative erythrocyte maximizing 
and/or blood conservation 
Fe supplementation, vitamines (C, 
folates, B12), short-course 
erythropoietin, 
Autologous blood donation of 1-3 units: 
a: blood bank center collection 
b: perioperative isovolemic 
hemodiloution 
Bleeding minimization Sophisticated technology of incision 
(argon atmosphere, laser scalpel,…) 
Refinements of surgical methods 
Topical hemostatic agents 
Peroperative blood recuperation 
Postoperative blood salvage 
Early revision for surgical bleeding 
Hemodilution minimization during 
CPB 
Low priming volume and retrograde  
priming after starting CPB 
Ultrafiltration 
Minicircuits 
Homeostasis optimization Controlled hemostasis ( blood fluidity ) 
Controlled hemodynamics ( blood 
pressure ) 
Normothermia 
Internal environment (pH, blood gases, 
ionts, glycaemia ) 
Adherence to basic rule of  transfusion  Complying with lowest and safe level of 
anemia for a given clinical case 
STS recommended transfusion point: 
Hb 7 ± 1 g/dl . 
Table 1. Policy for limitation of blood bank transfusion in cardiac surgery 
2.1 Pre-operative autologous blood donation 
The efficacy of pre-operative blood donation varies according to the time between blood 
collection and cardiac surgery. The current storage and preservation techniques allow us to 
collect and maintain 2 to 4 units of full blood or PRBCs. This efficacy can be enhanced by 
stimulation of erythropoiesis during blood donation, but this is used only selectively 
because of the potential of thrombotic cardiovascular events and costs [11, 12]. The use of 
erythropoietin is also limited by the necessity of starting its administration 3 weeks before 
surgery [13]. A short course erythropoietin was also used several days before cardiac 
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operation in anemic patients (haemoglobin < 13 g/dl) without autologous predonation [14, 
15]. In cardiac patients, there are certain contraindications for participation in autologous 
blood donation programmes; in addition to anaemia (haematocrit below 33%), they include 
critical aortic stenosis, idiopathic subaortal stenosis, ischaemic heart disease with unstable 
angina or with left main coronary artery stenosis, chronic NYHA class IV heart failure, 
ventricular rhythm disturbances on the day of blood collection and an acute heart attack. 
This all narrows the selection of candidates for autologous blood donation in cardiac 
surgery. The proportion of patients meeting the criteria for autotransfusion varies from 10% 
to 30%; however, some centres can indicate more patients in relation to the range of surgical 
procedures done and according to experience of the blood collection team. 
Intra-operative isovolaemic haemodilution 
Blood collection performed immediately before cardiac surgery for the purpose of acute 
isovolaemic haemodilution is also included in an autologous blood donation programme, 
thus permitting participation of the patients otherwise contraindicated for a standard 
programme [16]. A 500- to 1000-ml amount of blood is collected via a central venous 
catheter or an arterial line and is replaced by a colloid or crystalloid solution before 
cardiopulmonary bypass (CPB) surgery is commenced. For calculation of the final 
haematocrit (HCT) value, it is necessary to take the CPB dilutional effect (minimum of 1.3 l) 
into consideration. Usually, a dilution of 25% to 20 % HCT is used, which is also 
recommended because of a lower risk of damage to blood elements during extracorporeal 
perfusion. In some centres, 15% HCT is an accepted transfusion trigger in the patients who 
do not tolerate allogeneic blood transfusion [17, 18]. 
The advantage of intra-operative haemodilution is in that the lost blood contains lower red 
blood cell counts and a transfusion of fresh autologous blood supplies functional platelets. 
The only contraindication for intra-operative isovolaemic haemodilution is anaemia and 
haemodynamic instability. Patients with a cardiac disease and a haemoglobin level below 
130 g/l may not be able to compensate for a temporary decrease in erythrocyte counts and 
may show signs of tissue hypoxia or symptoms of cardiac disease. This approach can be 
combined with blood processing by apheresis. 
Intra-operative apheresis 
It was first used in thoracic surgery in 1987. It is a medical technology in which the blood of 
a patient is passed through an apparatus that separates out plasma and platelets and returns 
the reminder to the circulation. The separated components are then ready for use at the time 
needed to complete their deficiency. During cardiac surgery with extracorporeal circulation, 
this technology can also salvage part of the platelets which are otherwise absorbed onto the 
inner surface of the extracorporeal tubing or can end as platelet-leukocytes micro-aggregates 
in the capillary beds. The anaesthesiologist can decide between plasma with platelets or a 
platelet concentrate requiring a slowly rocking shaker for short-term maintenance. Similarly 
to many blood recuperation devices, the apheresis technique is based on centrifugal force. 
The proportion of platelets in plasma depends on the spin rate (2400-3600 revolutions per 
min). The amount of plasma safely collected is related to the patient’s clinical condition and 
usually equals to 20 % of the calculated plasma volume or 12 ml/kg body weight. The 
procedure design for replenishing intravascular volume, which differs from centre to centre, 
involves crystalloids and starch derivatives or albumin. When a larger amount of blood is 
collected, it is necessary to check the ionogram, pH value and free calcium and magnesium 
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levels. The efficiency of both plasmapheresis and thrombopheresis has been evaluated in 
many studies. Some have reported lower requirements for allogeneic blood transfusion [19, 
20, 21] as well as lower post-operative blood losses [22]. A positive effect of pre-operative 
plasmapheresis has been demonstrated by low tendency to pathological fibrinolysis [23]. On 
the other hand, other authors described a low efficacy of pre-operative apheresis in cardiac 
surgery [24] and related it to the pre-operative administration of an anticoagulation and 
platelet anti-aggregation therapy. The patients who, before surgery, have received coumarin 
derivatives, heparin and non-steroidal anti-phlogistic drugs do not benefit from 
plasmapheresis [25].  
2.2 Intra-operative blood salvage 
The collection of blood shed from the wound is an integral part of CPB surgery. The 
procedure consists of two steps, namely, cardiotomy suction carried out during CPB with 
standard heparinisation and blood recuperation during normocoagulation. 
Cardiotomy suction 
The system is usually composed of two suction lines, two pumps and a cardiotomy 
reservoir with filters. Blood is retrieved not  only from some heart and aorta sections, but 
also directly from the operative field which continually fills with blood coming from the 
open sternum and  the mediastinum, and from around the cannulae connecting the circuit. 
The shed blood is aspirated and collected in the reservoir, passes through a filter and is 
returned via an oxygenator into the circulation. The patient can thus be re-infused with 
several litres of blood. However, during this process blood is exposed to air in the operative 
wound and to synthetic surfaces of tubing, which activates a non-specific inflammatory 
response including coagulation. Suction-produced mechanical stress results in damage to 
erythrocytes and contributes to haemolysis. An improvement could be achieved by 
processing shed mediastinal blood in an autotransfusion device that would separate viable 
erythrocytes from the rest of activated blood with cellular detritus, fat and vasoactive 
mediators. A good effect on pulmonary function and haemodynamics has been shown in 
patients receiving processed blood [26]. This technique, however, is not much used because 
of technical problems with processing large volumes of blood and the necessity of plasma 
and platelet substitution. 
Blood recuperation 
The processing of blood drained from the operative wound is carried out at the time the 
patient is not fully heparinised, i.e., before the beginning or after the end of extracorporeal 
perfusion. If, after the termination of perfusion, a large volume of blood with low HCT is left 
in the reservoir, its recuperation is advisable, particularly when problems with renal 
function are expected. A large reservoir blood volume can be avoided by inserting a 
haemofiltration coil in the CPB system. The approach, however, removes only water and 
low-molecular-weight substances. 
From the clinical point of view, the patient always benefits from blood recuperation 
because no or only few blood products are necessary [27]. In terms of costs, the situation 
depends on the degree of bleeding. With current blood products prices on the one hand 
and the costs of a recuperation set on the other, the results are equal if at least two PRBC 
units are obtained. It means that recuperation is cost-effective in patients with excessive 
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blood loss; the costs of both approaches are equal in patients with large blood loss and, in 
patients with low blood loss, recuperation comes at an increased cost to the institution 
[28]. This medico-economic analysis would be right on the assumption that transfusion of 
allogeneic PRBCs is as valuable as fresh autologous blood transfusion. The present-day 
evidence suggests that this is not true, although the major risks of allogeneic blood 
transfusion, such as infection or immunomodulation, are minimal. Packed red blood cells 
are more suitable for correcting severe chronic anaemia than for an acute large blood loss. 
Transfused banked erythrocytes are not capable of immediate oxygen release for tissue 
supply, and their accumulation in the pulmonary vascular bed may do acute damage to 
the lung tissue, causing right-sided pulmonary failure and paradoxically making 
circulatory shock worse. Nonetheless, for a patient with excessive blood loss, allogeneic 
blood transfusion is the only possible choice. Because of increasing awareness of these 
facts, blood recuperation is becoming a routine method in a growing number of centres 
for cardiac surgery and is currently used in about 50% and 60 % of these institutions in 
the EU and North America, respectively. 
2.3 Post-operative blood salvage 
The method of collection and re-infusion of mediastinal blood shed during surgery and 
drained in the early post-operative period has been used in cardiac surgery since 1978 
[29]. The blood is collected into a special auto-transfusion device, or the cardiotomy 
reservoir of a CPB system can be used when it is connected to mediastinal drainage and a 
vacuum generator and with anti-coagulation citrate solution added. The cardiotomy 
reservoir involves a 40- filter, but insertion of an additional 20- filter in the outlet line is 
recommended. The salvaged blood has 20-25% HCT, a small number of platelets, free 
haemoglobin and no fibrinogen. It also contains fibrin-degradation products, cardiac 
enzymes and other inflammatory factors which may adversely affect biochemical tests 
and clinical outcomes [30, 31]. In spite of the disadvantages, this is a safe technique which 
can reduce demands for blood transfusion particularly in patients with blood loss 
exceeding 500 ml in the first two hours [32]. Doubts concerning the quality of salvaged 
erythrocytes were challenged by Schmidt et al. who did not find any differences in 
survival between the red blood cells of shed mediastinal blood and those of circulating 
blood [33]. At present the use of a recuperation technique for mediastinal blood is 
preferred because it reduces the organism’s burden by free haemoglobin and 
inflammation mediators [34]. It is usually carried out in continuation of intra-operative 
recuperation and is regarded as a safe method up to 8 hours of the patient’s transfer to an 
intensive care unit [35].  
3. Blood bank products 
A rational therapy with blood products and derivatives requires that their administration 
be based on a documented deficiency or dysfunction. However, surgical bleeding may be 
associated with additional haemostatic risk factors. A prolonged hypovolaemia with 
subsequent shock can initiate consumption coagulopathy and the substitution with 
crystalloids and colloids will result in clotting factor dilution. With the exception of 
patients with serious vascular disease or very old persons, the majority of patients can 
tolerate anaemia with a haemoglobin concentration of 7 g/dl or 24% HCT. However, in 
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the early phase of circulatory and haemostatic homeostasis, it is advisable to increase Hb 
concentration to 8g/dl in order to spare the compensatory capacity of myocardium 
(increased cardiac output) and to utilise a possibility to regulate systemic blood pressure 
by blood viscosity. In patients with serious peripheral arterial disease, it is reasonable to 
increase the transfusion trigger. Transfusion should be administered only after the 
patient’s medical history and their actual health status have been taken into consideration 
[36, 37].  
3.1 Allogenic blood transfusion 
In cardiac surgery, blood transfusion is indicated to correct severe anaemia due to excessive 
bleeding caused by vessel disruption during surgical exposure and dissection or by 
coagulopathy. Severe anaemia is characterised by a decrease in Hb concentration which 
leads to diffuse or localised tissue ischaemia. The attitudes to indications for transfusion 
have developed under the influence of diverse subjective views, ranging from a miraculous 
remedy to an absolute refusal, as well as on evidence-based information. Patients can 
greatly benefit from blood transfusion, if it is life-saving, or be severely harmed if a serious 
infection is transferred. The risk of viral infection transfer has recently decreased so much 
(HIV or HCV transfer is one per million transfusions) that it should no longer be a limiting 
factor in blood transfusion [37]. 
Transfusion can also induce immunomodulation in the recipient, i.e., stimulation or 
inhibition of immune responses.. The former involves the production of antibodies 
(alloimmunisation) against the surface antigens including HLA, which has several 
adverse effects. The latter, immune depression, involves a decrease in the ratio of 
circulating T-lymphocyte subpopulations (CD4+/CD8+) and impaired function of natural 
killer cells and antibody production by lymphocytes. The development of 
immunomodulation is associated with donor leukocytes; their removal can by half reduce 
the incidence of adverse conditions, such as transfusion-related acute lung injury (TRALI) 
[38]. In addition, immunomodulation can enhance susceptibility to infection, as suggested 
by a strong association found between transfusion and post-operative infection in a 
retrospective study on 15 000 patients surgically treated for ischaemic heart disease in 
Cleveland in 2006 [39]. 
Blood transfusion offers three advantages: it increases blood oxygen-carrying capacity, 
provides volume to support cardiac output and improves homeostasis; however, only the 
first one is the indication criterion. Which situation, therefore, requires an increase in 
oxygen-binding capacity of the blood by means of transfusion? A defined threshold Hb 
concentration is not the answer, because the capacity of blood to transport oxygen depends 
on other parameters such as cardiac output, pulmonary oxygenation, and haemoglobin 
ability to bind and release oxygen. Nevertheless, based on studies and expert opinions, a 
consensus has been reached that transfusion is beneficial to patients with an Hb 
concentration below 7 g/dl while it brings no benefits to patients with an Hb level above 10 
g/dl. Moreover, an increase in oxygen-carrying capacity by transfusion is not accompanied 
by an immediate increase in oxygen delivery to tissues, because stored erythrocytes are 
depleted of 2, 3-diphosphoglycerate and nitric oxide concentrations, which markedly 
reduces their ability to offload oxygen. To recover this ability takes several hours, and blood 
bank transfusion thus only adds to haemodilution of functional haemoglobin and a transient 
drop in oxygen supply. 
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In healthy individuals, an acute anaemic state no longer manageable by compensatory 
mechanisms and leading to a switch to anaerobic metabolism occurs at Hb levels between 3 
and 4 g/dl. This is associated with venous haemoglobin oxygen saturation of 56%, which 
equals to a tissue supply of 333 ml oxygen/min/m2. The major compensatory mechanisms 
include increased cardiac output, an increase in oxygen extraction and an increase in 
capillary erythrocyte transit time. Patients with coronary heart disease may develop acute 
anaemia at an Hb level of about 6 g/dl. These limit values have been obtained in animal 
experiments and confirmed by cardiac surgery in several thousands of Jehovah’s Witness 
patients. The level of evidence, defined as C and D, allows us to accept the fact that, in 
certain clinical situations, patients can tolerate an Hb concentration of about 6 g/dl. The 
range of clinical conditions is very broad and, in the present-day ageing polymorbid 
population, there are not many patients who would tolerate acute anaemia with threshold 
Hb values 6 g/dl. 
3.2 Fresh frozen plasma (FFP) 
Full blood collected from donors is treated by plasmapheresis or centrifugation to obtain 
plasma which is frozen within 6 hours of collection. Although FFP is indicated for 
documented either isolated or multiple coagulation factor deficiencies (II, V, VII, IX, X, 
XII), it has formerly been used as volume replacement and in the prophylaxis of potential 
coagulopathy in relation to massive transfusions and extracorporeal circulation. At the 
1984 conference on FFP it was concluded that such indications for FFP administration are 
not justified and this conclusion has so far been accepted [40,10]. Prophylactic FFP 
administration on the basis of massive transfusion (more than 10 red blood cell mass 
units) and abnormal laboratory tests (PT and aPTT) in the absence of clinically apparent 
bleeding is not supported by evidence either. Abnormal PT and aPTT results are often 
found even after five administrations of blood transfusion. Their positive predictive value 
is only about 30%. However, patients in whom the blood transfusion volume exceeds the 
total blood volume will always require either platelet substitution or FFP, or both 
products. A correlation between the volume of lost plus transfusion blood and the 
occurrence of coagulopathy is not a simple one. On the other hand, there is a strong 
correlation between the occurrence of coagulopathy and the duration of hypotension 
and/or hypothermia. Patients with no or only a short period of hypotension, even if they 
receive massive transfusion, will not have coagulopathy while those exposed to one hour 
of hypotension will often develop a serious form of it. Similarly, hypothermia plays an 
important role; its avoidance is a decisive factor in the prevention of coagulopathy after 
massive transfusion Patients undergoing cardiac surgery with extracorporeal circulation 
experience a drop in coagulation factor levels by 30 to 40 %, but only few of them show 
clinical bleeding. Excessive bleeding after cardiac surgery, if not due to surgical reasons, 
results from platelet dysfunction or their deficiency, and/or is caused by hypothermia, 
prolonged hypotension (circulatory shock) or residual heparinisation. Because of the lack 
of scientific evidence for clinical efficacy, indication criteria for the use of FFP are largely 
based on cardiac surgeons’ expertise. They include: 1) substitution therapy in isolated or 
multiple coagulation factor deficiencies.; 2) need to reverse over-warfarinisation, in that 
case two units are administered in the  non-bleeding patient and six units in the bleeding 
one; 3)  treatment of pathological bleeding due to a transfusion volume being  larger than 
the patient’s total blood volume. 
www.intechopen.com
 
Perioperative Considerations in Cardiac Surgery 
 
174 
3.3 Thrombocyte concentrate (TC) 
Thrombocyte concentrates are transfusion products obtained from full blood by 
centrifugation. A pooled-donor TC is derived from four to six blood donors to give one 
therapeutic thrombocyte transfusion unit for an adult patient. A single-donor TC is obtained 
by apheresis using a platelet separator. Both products contain over 200 x 109 platelets in a 
250- to 350-ml plasma volume. The TCs are stored in special storage bags allowing gas 
exchange on a shaking apparatus at 20-24°C for up to 5 days. In TC infusion, the ABO-blood 
group/Rhesus factor of the patient must be respected. If a TC of the required blood group is 
not available, thrombocytes suspended in plasma ABO compatible with the recipient’s 
erythrocytes can be administered. Other options include a TC from an O-blood group donor 
who has a low titre of anti-A and anti-B agglutinins or the use of platelets resuspended in a 
plasma substitute. An Rh-positive donor can receive a TC from an Rh-negative donor, but 
not vice versa [41]. 
In major surgical procedures, it is recommended to maintain the platelet count above 50 
x109/l because of a risk for microvascular bleeding. In cardiac surgery with 
cardiopulmonary bypass, where platelet-related defects are the most frequent cause of 
haemostatic abnormality, the recommended platelet count is 50-100 x109/l [42]. An 
increase above this level is justified only in severe platelet dysfunction. Platelet 
concentrates should not be administered routinely in cardiac surgery because it has been 
associated with increase in multi-organ failure and death [43, 44]. One therapeutic TC unit 
in an adult patient increases the platelet count by 10-20 x109/l. The therapeutic efficacy is 
assessed by clinical signs (decrease of bleeding) or laboratory evidence of increased platelet 
counts. 
An insufficient increase in platelet counts can be due to reasons such as low TC quality or 
higher requirements for platelet counts in patients with trauma or disseminated 
intravascular coagulation. However, the most serious cause involves immune destruction of 
platelets by alloantibodies or autoantibodies, and this is suspected when other causes are 
excluded. 
4. Blood bank transfusion for urgent procedures 
In transfusion practice safety requires that allogeneic blood be cross-matched with the 
recipient’s blood; the test takes about 60 min. In emergency live-saving procedures or 
unexpected massive blood losses, it is possible to perform transfusion after a minor cross-
match test or without it, or to administer ABO/Rh compatible blood or O-type blood.  
If immediate transfusion is necessary and the recipient’s blood group is not known, then it is 
justified to use uncrossmatched type-O packed red blood cells (UORBC) that lack A and B 
surface antigens. For potential expecting mothers, the UORBCs should always be Rh 
negative to avoid sensibilisation and damage to the foetus in case the mother is Rh-negative. 
The patients should be given no more that 10 UORBC units and subsequently receive 
transfusion with standard blood testing. 
If there is time to do blood group testing, ABO-compatible PRBCs are administered without 
a cross-match test. 
In about 3 % of the human population, serum contains anti-erythrocyte antibodies which in 
a great majority (85 %) are of one type only. The magnitude of risk for a post-transfusion 
reaction is equal to this frequency, but the results from trauma centres show that it is in fact 
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even lower. Gervin et al. have recorded no reaction in 875 transfusions without cross-
matching in 160 patients [45]. 
When more time is available (about 20 min), a minor cross-match test is done which reveals 
most of the donor uncommon anti-erythrocyte antibodies. It fails to detect abnormal 
antibodies in only 0.04% of the patients and this makes the probability of post-transfusion 
reaction extremely low. 
It can be concluded that, seen in a historical perspective, the needs for blood transfusion in 
cardiac surgery have varied, but are still high. With advances in cardiac surgery during the 
last 50 years, a significant decrease was recorded in the average blood product requirement 
per patient, but this trend has recently had declining tendency. The reason lies in increasing 
numbers of reoperations and surgery on very old and polymorbid patients with 
preoperative anemia. Our conclusion suggests a multi-modality blood-saving strategy 
ranging from patient pre-operative preparation, over surgical and autotransfusion 
techniques and drug intervention to homeostatic maintenance. So far this strategy has 
brought about results in the form of an increasing number of operations not requiring 
transfusion; this is currently more than 50 % of all cardiac surgery procedures. Despite its 
risks, allogenic blood transfusion still remains an important supportive and life-saving 
measure in ultimate situations. 
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